Nuvaring

Leaflet accompanying the packaging: user information

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

NuvaRing (Circlet)

(0.120 mg + 0.015 mg)/24 h, vaginal therapeutic system
Etonogestrel + Ethinylestradiol
NuvaRing and Circlet are different trade names for the same drug.

Important information about combined hormonal contraceptives

• If used correctly, they are one of the most reliable, reversible methods of contraception.
• To a small extent, they increase the risk of blood clots in veins and arteries, especially in the first year of use or after resuming use after a break of 4 weeks or more.
• One should be vigilant and consult a doctor if the patient suspects that symptoms of blood clots have occurred (see section 2 "Blood clots").

One should carefully read the contents of the leaflet before using the drug, as it contains important information for the patient.

• One should keep this leaflet, so that it can be re-read if necessary.
• In case of any doubts, one should consult a doctor or pharmacist.
• This drug has been prescribed to a specific person. It should not be given to others. The drug may harm another person.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is NuvaRing and what is it used for
• 2. Important information before using NuvaRing
• 3. How to use NuvaRing
• 4. Possible side effects
• 5. How to store NuvaRing
• 6. Package contents and other information

1. What is NuvaRing and what is it used for

NuvaRing is a contraceptive in the form of a vaginal therapeutic system, preventing pregnancy. Each vaginal therapeutic system contains a small amount of two female sex hormones - etonogestrel and ethinylestradiol. These hormones are slowly released from the system into the bloodstream. Due to the small dose of hormones released, NuvaRing is classified as a low-hormone contraceptive. Since NuvaRing releases two different hormones, it is also a combined contraceptive.
NuvaRing works like a tablet containing a combined contraceptive (combined tablet), but unlike a tablet that must be taken daily, NuvaRing is used for 3 weeks in a row. NuvaRing releases two female sex hormones that inhibit the release of egg cells from the ovaries. Since egg cells are not released, the patient cannot become pregnant.

2. Important information before using NuvaRing

Page 1 of 18

General notes

Before starting to take NuvaRing, one should familiarize themselves with the information about blood clots (thrombosis) in section 2. It is especially important to familiarize oneself with the symptoms of blood clots (see section 2 "Blood clots").
This leaflet describes situations in which one should stop using NuvaRing or in which its effectiveness may be reduced. In these situations, one should refrain from sexual intercourse or use an additional contraceptive method, other than hormonal, such as a male condom or another mechanical method. One should notuse methods based on a calendar or body temperature measurement. They may be ineffective, as NuvaRing affects changes in body temperature and cervical mucus consistency throughout the month.

NuvaRing, like other hormonal contraceptives, does not protect against HIV (AIDS) or other sexually transmitted diseases.

2.1 When not to use NuvaRing

NuvaRing should not be used if the patient has any of the following conditions. If the patient has any of the following conditions, they must inform their doctor. The doctor will discuss with the patient which other contraceptive method will be more suitable.

• if the patient currently has (or has ever had) a blood clot in the veins of the legs (deep vein thrombosis), in the lungs (pulmonary embolism), or in other organs,
• if the patient knows they have blood coagulation disorders - such as protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden, or antiphospholipid antibodies,
• if the patient requires surgery or will be immobilized for a long time (see section "Blood clots"),
• if the patient has had a heart attack or stroke,
• if the patient has (or has had in the past) angina pectoris (a disease that causes severe chest pain, which can be the first symptom of a heart attack) or transient ischemic attack (transient stroke symptoms),
• if the patient has any of the following diseases, which may increase the risk of arterial thrombosis:
• severe diabetes with vascular damage
• very high blood pressure
• very high levels of fats in the blood (cholesterol or triglycerides)
• hyperhomocysteinemia
• if the patient has (or has had in the past) a type of migraine called "migraine with aura",
• if the patient has (or has had in the past) pancreatitis associated with high levels of fats in the blood,
• if the patient has (or has had in the past) severe liver disease, and liver function has not returned to normal,
• if the patient has (or has had in the past) a benign or malignant liver tumor,
• if the patient has (or has had in the past) breast cancer or genital cancer, or if there is a suspicion of these cancers,
• if the patient has unexplained vaginal bleeding,
• if the patient is allergic to ethinylestradiol or etonogestrel or any of the other ingredients of this drug (listed in section 6).

Page 2 of 18
If any of the above symptoms occur for the first time during NuvaRing use, the system should be removed from the vagina immediately and a doctor should be consulted, and a non-hormonal contraceptive method should be used during this time.
If the patient has hepatitis C and is taking drugs containing ombitasvir, paritaprevir, ritonavir, and dasabuvir or glecaprevir, pibrentasvir, NuvaRing vaginal therapeutic system should not be used (see also section 2.4 "NuvaRing and other drugs").

2.2 Warnings and precautions

When to contact a doctor?
One should immediately consult a doctor

• if the patient notices probable symptoms of blood clots, which may indicate that the patient has blood clots in the leg (deep vein thrombosis), blood clots in the lungs (pulmonary embolism), heart attack, or stroke (see below "Blood clots"). To get a description of these serious side effects, see "How to recognize blood clots".

One should tell the doctor if the patient has any of the following conditions.

If these symptoms occur or worsen during NuvaRing use, one should also tell the doctor.

• if breast cancer occurs or has occurred in close relatives;
• if the patient has epilepsy (see section 2.4 "NuvaRing and other drugs");
• if the patient has liver disease (e.g., jaundice) or gallbladder disease (e.g., gallstones);
• if the patient has Crohn's disease or ulcerative colitis (chronic inflammatory bowel diseases);
• if the patient has systemic lupus erythematosus (a disease that affects the natural defense system);
• if the patient has hemolytic uremic syndrome (a blood clotting disorder that causes kidney failure);
• if the patient has sickle cell anemia (a hereditary disease of red blood cells);
• if the patient has a history of high levels of fats in the blood (hypertriglyceridemia) or a family history of this disease. Hypertriglyceridemia is associated with an increased risk of developing pancreatitis;
• if the patient requires surgery or will be immobilized for a long time (see section 2 "Blood clots");
• if the patient has recently given birth, as they are at increased risk of blood clots. One should consult a doctor to find out how soon they can start using NuvaRing after giving birth;
• if the patient has superficial thrombophlebitis (blood clots in the veins under the skin);
• if the patient has varicose veins;
• if the patient has diseases that occurred for the first time or worsened during pregnancy or previous use of sex hormones (e.g., hearing loss, porphyria [a blood disease], pregnancy herpes [a blistering skin rash during pregnancy], or Sydenham's chorea [a neurological disorder characterized by involuntary, sudden movements of the body]),
• one should consult a doctor immediately if symptoms of angioedema occur, such as swelling of the face, tongue, and/or throat, and/or difficulty swallowing or occurrence of hives that may be associated with difficulty breathing. Drugs containing estrogens may cause or worsen symptoms of hereditary and acquired angioedema;

Page 3 of 18
Drugs containing estrogens may also cause or worsen the symptoms of chloasma (yellow-brown pigmentation spots, so-called "pregnancy spots", especially on the face). If they occur, one should avoid excessive sun exposure and ultraviolet radiation;

• if the patient has conditions that make it difficult to use NuvaRing, such as frequent constipation, cervical prolapse, or pain during intercourse;
• if the patient has sudden, frequent need to urinate with a burning sensation and/or pain, and if the patient cannot locate the vaginal therapeutic system inside the vagina. These symptoms may indicate that the vaginal therapeutic system has been accidentally inserted into the bladder.

BLOOD CLOTS

The use of combined hormonal contraceptives, such as the NuvaRing vaginal therapeutic system, is associated with an increased risk of blood clots, compared to not using the therapy. In rare cases, a blood clot can block a blood vessel and cause serious complications.
Blood clots can occur

• in veins (hereinafter referred to as "venous thromboembolism" or "venous thromboembolic disease");
• in arteries (hereinafter referred to as "arterial thromboembolism" or "arterial thromboembolic disease").

Not always is there a complete recovery after a blood clot. In rare cases, the effects of a blood clot can be permanent or, very rarely, fatal.

It should be remembered that the total risk of harmful blood clots caused by NuvaRing is small.

HOW TO RECOGNIZE BLOOD CLOTS

One should immediately consult a doctor if they notice any of the following symptoms.
Is the patient experiencing any of these symptoms?
Why is the patient likely to suffer

• swelling of the leg or swelling along a vein in the leg or foot, especially if it is accompanied by:
• pain or tenderness in the leg, which can only be felt while standing or walking,
• increased temperature in the affected leg,
• change in skin color of the leg, such as pallor, redness, or cyanosis. Deep vein thrombosis
• sudden unexplained shortness of breath or rapid breathing;
• sudden unexplained cough, which may be accompanied by coughing up blood;
• sharp chest pain, which may worsen with deep breathing;
• severe dizziness or fainting;
• rapid or irregular heartbeat;
• severe stomach pain; If the patient is unsure, they should consult a doctor, as some of these symptoms, such as coughing or shortness of breath, may be mistaken for milder conditions, such as a respiratory infection (e.g., a cold).

Page 4 of 18

may be mistaken for milder conditions, such as a respiratory infection (e.g., a cold).
Symptoms usually occur in one eye: immediate vision loss or painless vision disturbances, which can lead to vision loss	Retinal vein thrombosis (blood clot in the eye)
chest pain, discomfort, pressure, or heaviness; a feeling of squeezing or fullness in the chest, arm, or below the breastbone; a feeling of fullness, indigestion, or choking; a feeling of discomfort in the lower body radiating to the back, jaw, throat, arm, and stomach; sweating, nausea, vomiting, or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeat.	Heart attack
sudden weakness or numbness of the face, arms, or legs, especially on one side of the body; sudden confusion, speech disturbances, or difficulty understanding; sudden vision disturbances in one or both eyes; sudden walking disturbances, dizziness, loss of balance, or coordination; sudden, severe, or prolonged headaches without a known cause; loss of consciousness or fainting with or without seizures. In some cases, stroke symptoms may be transient with almost immediate and complete recovery, but one should still consult a doctor immediately, as they may be at risk of having another stroke.	Stroke
swelling and slight bluish discoloration of the skin of the legs or arms severe stomach pain (acute abdomen)	Blood clots blocking other blood vessels

BLOOD CLOTS IN VEINS

What can happen if blood clots form in a vein?

• The use of combined hormonal contraceptives is associated with an increased risk of blood clots in the veins (venous thromboembolism). Although these side effects are rare, they can occur, especially in the first year of using combined hormonal contraceptives.
• If blood clots form in the veins of the leg or foot, it can lead to the development of deep vein thrombosis.
• If a blood clot moves from the leg and settles in the lungs, it can cause pulmonary embolism.
• In very rare cases, a blood clot can form in another organ, such as the eye (retinal vein thrombosis).

When is the risk of blood clots in a vein the highest?

The risk of forming blood clots in a vein is highest during the first year of using combined hormonal contraceptives for the first time. The risk may also be higher when resuming the use of combined hormonal contraceptives (the same or a different drug) after a break of 4 weeks or more.
Page 5 of 18
After the first year, the risk decreases, but it is always higher compared to not using combined hormonal contraceptives.
If the patient stops using NuvaRing, the risk of blood clots returns to a normal level within a few weeks.

What affects the risk of blood clots?

The risk depends on the natural risk of venous thromboembolism and the type of combined hormonal contraceptive used.
The total risk of blood clots in the legs or lungs associated with NuvaRing is small.

• During a year, about 2 out of 10,000 women who do not use combined hormonal contraceptives and are not pregnant will develop blood clots.
• During a year, about 5-7 out of 10,000 women who use combined hormonal contraceptives containing levonorgestrel, norethisterone, or norgestimate will develop blood clots.
• During a year, about 6-12 out of 10,000 women who use combined hormonal contraceptives containing norelgestromin or etonogestrel, such as NuvaRing, will develop blood clots.
• The risk of blood clots depends on the patient's individual medical history (see "Factors that increase the risk of blood clots", below).

	Risk of blood clots in a year
Women who do not use combined hormonal pills/patches/systems and are not pregnant	About 2 out of 10,000 women
Women using combined hormonal contraceptive pills containing levonorgestrel, norethisterone, or norgestimate	About 5-7 out of 10,000 women
Women using NuvaRing vaginal therapeutic system	About 6-12 out of 10,000 women

Factors that increase the risk of blood clots in veins

The risk of blood clots associated with NuvaRing is small, but some factors can increase this risk.
The risk is higher:

• if the patient is significantly overweight (body mass index (BMI) over 30 kg/m);
• if someone in the patient's close family has had blood clots in the legs, lungs, or other organs at a young age (e.g., under 50 years old). In this case, the patient may have hereditary coagulation disorders;
• if the patient must undergo surgery, is immobilized for a long time due to injury or illness, or has a leg in a cast. It may be necessary to stop using NuvaRing for a few weeks before surgery or immobilization. If the patient must stop using NuvaRing, they should ask their doctor when they can resume using it;
• with age (especially over 35 years old);
• if the patient has recently given birth.

The risk of blood clots increases with the number of risk factors present in the patient.
Long-distance air travel (>4 hours) may temporarily increase the risk of blood clots, especially if the patient has another risk factor.
It is essential to tell the doctor if any of these factors are present, even if the patient is unsure. The doctor may decide to stop using NuvaRing.
Page 6 of 18
One should inform the doctor if any of the above conditions change during NuvaRing use, e.g., if someone in the patient's close family is diagnosed with thrombosis without a known cause or if the patient gains significant weight.

BLOOD CLOTS IN ARTERIES

What can happen if blood clots form in an artery?

Similarly to blood clots in veins, blood clots in arteries can have serious consequences, such as a heart attack or stroke.

Factors that increase the risk of blood clots in arteries

It is essential to note that the risk of heart attack or stroke associated with NuvaRing is very small, but it may increase:

• with age (over approximately 35 years old);
• if the patient smokes. While using a hormonal contraceptive like NuvaRing, it is recommended to quit smoking. If the patient is unable to quit smoking and is over 35 years old, the doctor may recommend using a different type of contraception;
• if the patient is overweight;
• if the patient has high blood pressure;
• if someone in the patient's close family has had a heart attack or stroke at a young age (under 50 years old). In this case, the patient may also be at increased risk of having a heart attack or stroke;
• if the patient or someone in their close family has high levels of fats in the blood (cholesterol or triglycerides);
• if the patient has migraines, especially migraines with aura;
• if the patient has heart disease (valve damage, arrhythmia called atrial fibrillation);
• if the patient has diabetes.

If the patient has more than one of the above conditions or if any of them are particularly severe, the risk of blood clots may be even higher.
One should inform the doctor if any of the above conditions change during NuvaRing use, e.g., if the patient starts smoking, someone in their close family is diagnosed with thrombosis without a known cause, or if the patient gains significant weight.

Cancer

The following information is based on studies using combined oral contraceptives and may also apply to NuvaRing. Information on vaginal use of hormonal contraceptives (as with NuvaRing) is not available.
In women using combined contraceptives, a slightly higher incidence of breast cancer has been found, although it is not known whether this is caused by the drugs being used. It is possible that in women using combined contraceptives, tumors are detected more often because these women are more likely to undergo medical examinations. The increased incidence of breast cancer gradually decreases after stopping the use of combined contraceptives.
Regular breast examination is very important. If a lump is found, one should consult a doctor. One should also inform the doctor if breast cancer has occurred or is occurring in close relatives (see section 2.2 "Warnings and precautions").
Page 7 of 18
In rare cases, women using combined contraceptives have developed benign liver tumors, and very rarely, malignant tumors as well. If unusual, severe abdominal pain occurs, one should consult their doctor.
There are reports that women using combined contraceptives less often develop endometrial cancer (cancer of the uterine lining) and ovarian cancer. It is possible that this also applies to NuvaRing, but this has not been confirmed yet.

Mental disorders

Some women using hormonal contraceptives, including NuvaRing, have reported depression or low mood. Depression can be severe and sometimes lead to suicidal thoughts. If mood changes and symptoms of depression occur, one should consult a doctor as soon as possible to receive further medical advice.

2.3 Children and adolescents

The safety and efficacy of NuvaRing have not been studied in adolescents under the age of 18.

2.4 NuvaRing and other drugs

One should always tell their doctor about the drugs or herbal products they are currently using. One should also inform their doctor or another doctor prescribing other drugs (or pharmacist) about using NuvaRing. They may inform about the need to use an additional contraceptive method (e.g., a male condom), and if so, for how long, as well as whether it is necessary to modify the use of another drug.
Some drugs

• may affect the level of NuvaRing in the blood;
• may reduce its contraceptive effectiveness;
• may cause unexpected bleeding.

This applies to drugs used to treat:

• epilepsy (e.g., primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate);
• tuberculosis (e.g., rifampicin);
• HIV infection (e.g., ritonavir, nelfinavir, nevirapine, efavirenz);
• hepatitis C (e.g., boceprevir, telaprevir);
• other infectious diseases (e.g., griseofulvin);
• high blood pressure in the blood vessels of the lungs (bosentan);
• depressive moods (St. John's wort).

If the patient is taking drugs or herbal products that may reduce the effectiveness of NuvaRing, they should also use a mechanical contraceptive method (e.g., a male condom). Since the effect of another drug on NuvaRing may persist for up to 28 days after stopping the drug, it is necessary to use additional mechanical contraception during this time.
Note: NuvaRing should not be used with a diaphragm, cervical cap, or female condom.
NuvaRing may affect the action of other drugs, such as

• drugs containing cyclosporine
• the antiepileptic drug lamotrigine (this may lead to an increased frequency of seizures).

If the patient has hepatitis C and is taking drugs containing ombitasvir, paritaprevir, ritonavir, and dasabuvir or glecaprevir, pibrentasvir, they should not use the NuvaRing vaginal therapeutic system, as this may cause an increase in liver function test results in blood tests (an increase in the activity of the liver enzyme ALT).
Before starting these drugs, the doctor will prescribe a different type of contraceptive.
NuvaRing can be used again about 2 weeks after the end of this treatment. See section 2.1 "When not to use NuvaRing".
Before taking any drug, one should consult a doctor or pharmacist.
During NuvaRing use, tampons can be used at the same time. One should insert NuvaRing before inserting a tampon. One should be careful when removing a tampon to avoid accidentally removing NuvaRing as well. If NuvaRing is expelled, it is enough to rinse the vaginal therapeutic system with cold or warm water and reinsert it as soon as possible.
Damage to the vaginal therapeutic system has occurred during the use of vaginal products, such as moisturizers or treatments for infections (see section 3.4 "What to do if the vaginal therapeutic system is damaged"). The use of spermicides or vaginal antifungal drugs does not reduce the contraceptive effectiveness of NuvaRing.

Diagnostic tests

If laboratory blood or urine tests are being performed, one should inform the persons performing the tests about using NuvaRing, as the use of the vaginal therapeutic system may affect the results of some laboratory tests.

2.5 Pregnancy and breastfeeding

NuvaRing should not be used during pregnancy or if there is a suspicion that the woman is pregnant. If the patient becomes pregnant during NuvaRing use, they should remove the vaginal therapeutic system and consult a doctor.
If the patient wants to stop using NuvaRing because they want to become pregnant, they should read the information in section 3.5 "What to do if the patient wants to stop using NuvaRing".
NuvaRing should not be used during breastfeeding. If the patient wants to use NuvaRing during breastfeeding, they should first consult their doctor.

2.6 Driving and using machines

NuvaRing does not affect the ability to drive or operate machines.

3. How to use NuvaRing

NuvaRing can be inserted and removed by the patient themselves. The doctor will instruct when to start using NuvaRing. The vaginal therapeutic system should be inserted on the appropriate day of the cycle (see section 3.3 "When to insert the first NuvaRing vaginal therapeutic system") and left in place for 3 weeks in a row. One should regularly check if the NuvaRing vaginal therapeutic system is in the vagina (e.g., before and after sexual intercourse) to ensure contraceptive protection. After 3 weeks, one should remove NuvaRing and take a 1-week break. Usually, during this break, withdrawal bleeding occurs.
Page 9 of 18
One should not use certain mechanical contraceptive methods for women, such as a diaphragm, cervical cap, or female condom, while using NuvaRing. One should not use these mechanical contraceptive methods as an additional method of contraception, as NuvaRing may make it difficult to properly insert and position the diaphragm, cervical cap, or female condom. However, a male condom can be used as an additional mechanical contraceptive method.

3.1 Inserting and removing NuvaRing

• 1. Before inserting the system, one should check the expiration date (see section 5 "How to store NuvaRing").
• 2. Before inserting or removing the system, one should wash their hands.
• 3. One should choose the most comfortable position for insertion, e.g., standing with one leg raised, squatting, or lying down.
• 4. One should remove NuvaRing from the pouch.
• 5. Holding the system with the thumb and index finger, one should squeeze it and insert it into the vagina (see Figures 1-4). Alternatively, the system can be inserted using the NuvaRing Applicator (not included with the NuvaRing packaging). The NuvaRing Applicator may not be available in all countries. The correct position of NuvaRing is one in which it is not felt. If the system is uncomfortable, one should gently change the position of the NuvaRing system (e.g., push the system slightly deeper into the vagina) until they feel comfortable. The position of the system in the vagina does not affect its contraceptive effectiveness.
• 6. After 3 weeks, one should remove the system from the vagina. This can be done by hooking the index finger under the edge of the system or by grasping it with the index and middle fingers and pulling it out (Figure 5). If the patient is unable to locate the system in the vagina but cannot remove it, they should consult their doctor.
• 7. One should dispose of the used system with other household waste, preferably in a sealed pouch in which it was originally contained. One should not flush NuvaRing down the toilet.

Figure 1
Remove the system from the pouch

Figure 2
Squeeze the system
Page 10 of 18

Figure 3
Choose the most comfortable position

Figure 4A
Figure 4B
Figure 4C
Insert the system into the vagina with one hand (Figure 4A), if necessary, using the other hand to spread the labia. Place it inside the vagina so that it does not cause discomfort (Figure 4B). Leave the system in the vagina for 3 weeks (Figure 4C).

Figure 5
Remove the system from the vagina, hooking the index finger under the edge of the system or grasping it with the index and middle fingers and pulling it out.

3.2 Three weeks of use, one week of break

Page 11 of 18

• 1. The system must be in the vagina for 3 weeks without interruption, counting from the day of insertion.
• 2. After 3 weeks, one should remove it on the same day of the week it was inserted and at about the same time. For example, if NuvaRing was inserted on a Wednesday at around 10:00 PM, it should be removed on the Wednesday 3 weeks later, at around 10:00 PM.
• 3. After removing the system, one should take a 1-week break. During this time, bleeding may occur. It usually starts 2-3 days after removal.
• 4. A new system should be inserted exactly 1 week after the break (on the same day of the week as usual and at about the same time), even if bleeding is still occurring. If the insertion of the new system is delayed by more than 3 hours, its contraceptive effectiveness may be reduced. In such a case, one should follow the instructions in section 3.4 "What to do if the patient forgets to insert a new vaginal therapeutic system after the 1-week break".

If NuvaRing is used according to the above instructions, subsequent bleedings will usually occur every month on approximately the same days of the week.

3.3 When to insert the first NuvaRing vaginal therapeutic system

• -In the previous cycle, no hormonal contraceptive was usedInsert NuvaRing on the first day of the natural cycle (i.e., the first day of menstruation). NuvaRing is effective from the moment of insertion. There is no need to use any additional contraceptive methods. One can also start using NuvaRing between the 2nd and 5th day of menstruation, but in this case, during the first 7 days of NuvaRing use, an additional contraceptive method (such as a male condom) should be used. This recommendation only applies to the first use of NuvaRing.
• -In the previous month, the patient usedcombined hormonal contraceptive pillsOne should start using NuvaRing no later than the day following the break from the currently used drug. If the currently used drug also has pills that do not contain active substances, one should start using NuvaRing no later than the day after taking the last pill that does not contain active substances. In case of doubt about which pill is which, one should ask their doctor or pharmacist. One should not extend the break in using the current pills beyond the recommended period. If the patient has been taking their pills regularly and is sure they are not pregnant, they can stop taking the pills on any day and start using NuvaRing immediately.
• -In the previous month, the patient useda transdermal system (patch)One should start using NuvaRing no later than the day following the break from the transdermal system. One should not extend the break in using the transdermal system beyond the recommended period. If the patient has been using the transdermal system regularly and is sure they are not pregnant, they can stop using the transdermal system on any day and start using NuvaRing immediately.
• -In the previous month, the patient useda minipill (progestogen-only contraceptive)One can stop using the minipill on any day and start using NuvaRing the next day at the same time they would have taken the minipill. During the first 7 days of NuvaRing use, an additional contraceptive method (such as a male condom) should be used.

Page 12 of 18

• -In the previous month, the patient usedinjections or an implant, or an intrauterine system releasing progestogen [IUD]One should start using NuvaRing on the day of the next scheduled injection or on the day the implant or intrauterine system releasing progestogen is removed. During the first 7 days of NuvaRing use, an additional contraceptive method (such as a male condom) should be used.
• -After giving birthAfter giving birth, the doctor may recommend using NuvaRing only after the first menstruation. Sometimes, NuvaRing can be started earlier; the doctor will advise when. If the patient is breastfeeding and wants to use NuvaRing, they should discuss this with their doctor first.
• -After a miscarriageAccording to the doctor's instructions.

3.4 What to do if…

What to do if the vaginal therapeutic system is accidentally expelled from the vagina

NuvaRing may be accidentally expelled from the vagina, e.g., if it is inserted incorrectly, during tampon removal, during sexual intercourse, due to constipation, or due to uterine prolapse. Therefore, one should regularly check if the system is in the vagina (e.g., before and after sexual intercourse).

Note: The translation provided is a complete translation of the original text, maintaining all HTML structure, tags, and formatting exactly as provided, while only translating the text content within HTML tags and preserving all medical terminology accuracy in English.

3.5 Procedure when a patient wants to stop using NuvaRing

NuvaRing can be stopped at any time.
If the patient does not want to become pregnant, she should ask her doctor about other contraceptive methods.
If the patient stops using NuvaRing because she wants to become pregnant, she should wait until the first menstruation and then start trying to become pregnant. This will help determine the date of birth.

4. Possible side effects

Like all medicines, NuvaRing can cause side effects, although not everybody gets them. If any side effects occur, especially serious and persistent ones or changes in health that the patient considers related to the use of NuvaRing, the patient should consult a doctor.
All women using combined hormonal contraceptives have an increased risk of developing blood clots in the veins (venous thromboembolism) or blood clots in the arteries (arterial thrombosis). To obtain detailed information about the various risk factors associated with the use of combined hormonal contraceptives, the patient should refer to section 2 "Important information before using NuvaRing".
Page 15 of 18
If an allergy (hypersensitivity) to any of the components of NuvaRing occurs, it may manifest as (frequency not known): angioedema and/or anaphylactic reaction [swelling of the face, lips, tongue, and/or throat and/or difficulty swallowing] or the occurrence of urticaria potentially with difficulty breathing. In these cases, NuvaRing should be removed and a doctor consulted immediately (see also section 2.2 "Warnings and precautions").
Women using NuvaRing have reported the following side effects:
Common:may occur in up to 1 in 10 women

• abdominal pain, nausea
• vaginal infections by fungi (such as "thrush"); discomfort caused by the presence of the system in the vagina; genital itching; discharge
• headache or migraine; depressive mood; decreased libido
• breast pain; pelvic pain; painful menstruation
• acne
• weight gain
• system expulsion

Uncommon:may occur in up to 1 in 100 women

• vision disturbances; dizziness
• bloating; vomiting, diarrhea, or constipation
• fatigue, malaise, or irritability; mood changes; sudden mood changes
• edema
• urinary tract infections
• problems or pain during urination; urge to urinate or need to urinate frequently
• discomfort during intercourse, including pain, bleeding, inconvenience related to the presence of the system, felt by the partner
• increased blood pressure
• increased appetite
• back pain; muscle cramps; pain in the lower or upper limbs
• decreased skin sensitivity
• breast tenderness or enlargement; fibrocystic breast disease (lumps that can cause swelling or pain in the breast)
• cervicitis; cervical polyps; cervical ectropion
• changes in menstrual bleeding (e.g., heavy, prolonged, irregular, or complete absence of menstruation); pelvic discomfort; premenstrual syndrome; uterine cramps
• vaginal infections (fungal or bacterial); feeling of burning, unpleasant odor, pain, discomfort, or dryness of the vagina or vulva
• hair loss, rash, itching, or flushing
• urticaria

Rare:may occur in up to 1 in 1000 women

• harmful blood clots in a vein or artery, for example: in the leg or foot (e.g., deep vein thrombosis) in the lungs (e.g., pulmonary embolism) heart attack stroke transient ischemic attack or temporary stroke-like symptoms, known as a transient ischemic attack blood clots in the liver, stomach, and intestine, kidneys, or eye The probability of developing blood clots may be higher if the patient has other risk factors (see section 2 for more information on risk factors for blood clots and symptoms of blood clots).

Page 16 of 18
information about the risk factors for blood clots and symptoms of blood clots).

• galactorrhea

Unknown(frequency cannot be estimated from the available data)

• chloasma (brownish-yellow spots on the skin, especially on the face)
• partner's genital discomfort (such as irritation, rash, itching)
• inability to remove the therapeutic vaginal system without medical assistance (e.g., due to the therapeutic vaginal system adhering to the vaginal wall)
• vaginal wall damage related to damage to the therapeutic vaginal system

Women using combined hormonal contraceptives have reported breast cancer and liver tumors. For more information, see section 2.2 "Warnings and precautions", "Tumors".
NuvaRing may rarely be damaged. For more information, see section 3.4 "Procedure in case of damage to the therapeutic vaginal system".

Reporting side effects

If any side effects occur, including any side effects not listed in the leaflet, the patient should tell her doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, PL-02 222 Warsaw, tel.: +48 22 49-21-301, fax: +48 22 49-21-309, website: https://smz.ezdrowie.gov.pl
Reporting side effects will help gather more information on the safety of the use of NuvaRing.

5. How to store NuvaRing

The medicine should be stored out of sight and reach of children.
A doctor should be consulted in case of exposure of a child to the hormones contained in NuvaRing.
Do not store above 30°C. Store in the original packaging to protect from light and moisture.
Do not use NuvaRing after 4 months from the date of issue of the medicine in the pharmacy. The date of issue is stated on the box and on the sachet.
Do not use NuvaRing after the expiry date stated on the packaging. The expiry date means the last day of the given month.
Do not use NuvaRing if it has changed color or if there are any signs of deterioration.
The used therapeutic vaginal system should be disposed of in a regular household waste bin, preferably in a sealed sachet. NuvaRing should not be flushed down the toilet. Like other medicines, unused or expired systems should not be disposed of in the sewage system or household waste bins. The patient should ask her pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Page 17 of 18

6. Contents of the packaging and other information

What NuvaRing contains

• The active substances of NuvaRing are: etonogestrel (11.7 mg) and ethinyl estradiol (2.7 mg).
• The other ingredients are: poly(ethylene-vinyl acetate), 28% and 9% vinyl acetate (a type of plastic that does not dissolve in the body) and magnesium stearate.

Etonogestrel and ethinyl estradiol are released from the therapeutic vaginal system in amounts of 0.120 mg/day and 0.015 mg/day over a period of 3 weeks.

What NuvaRing looks like and what the packaging contains

NuvaRing is a flexible, transparent, colorless or almost colorless ring with an outer diameter of 54 mm.
Each therapeutic vaginal system is packaged in a separate foil sachet. The sachet can be opened and closed again. The sachets are placed in a cardboard box with a leaflet and stickers to help remember when to insert and remove NuvaRing.
The packaging contains 1 or 3 systems.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Germany, the country of export:

Organon Healthcare GmbH, Pestalozzistr. 31, 80469 Munich, Germany

Manufacturer:

N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Netherlands

Parallel importer:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
German export license number: 80333.00.00

Parallel import license number: 81/25

This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

NuvaRing
0.120 mg/ 0.015 mg/ 24 h, therapeutic vaginal system
Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom (Northern Ireland).

Date of revision of the leaflet: 28.02.2025

[Information about the trademark]
Page 18 of 18